Centene (CNC) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Centene is expected to report Q3 2026 results before the market opens on October 27. Analysts project earnings of $0.0956 per share and revenue of $47.11 billion.
• In the prior quarter, Centene reported $2.51 EPS, exceeding estimates by $1.42, while revenue rose 9.9% year over year to $53.58 billion.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $70.05; the stock recently traded at $68.59, near its 12-month high of $71.21.

Centene (NYSE:CNC - Get Free Report) is projected to release its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect Centene to announce earnings of $0.0956 per share and revenue of $47.11 billion for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Centene (NYSE:CNC - Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.51 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $1.42. Centene had a negative net margin of 2.51% and a positive return on equity of 12.12%. The business had revenue of $53.58 billion during the quarter, compared to analyst estimates of $47.64 billion. During the same quarter in the prior year, the business earned ($0.16) earnings per share. The firm's revenue for the quarter was up 9.9% on a year-over-year basis. On average, analysts expect Centene to post $4.89 EPS for the current fiscal year and $5.34 EPS for the next fiscal year.

Centene Stock Down 0.8%

NYSE CNC opened at $68.59 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.15 and a current ratio of 1.15. The firm has a 50-day simple moving average of $65.46 and a 200 day simple moving average of $60.12. Centene has a twelve month low of $31.63 and a twelve month high of $71.21. The stock has a market cap of $33.88 billion, a PE ratio of 13.33, a PEG ratio of 0.44 and a beta of 1.13.

Wall Street Analyst Weigh In

CNC has been the topic of several research reports. Raymond James Financial set a $75.00 price target on Centene in a research note on Tuesday, July 7th. Barclays reiterated an "overweight" rating and issued a $80.00 price objective (up from $75.00) on shares of Centene in a research report on Wednesday, July 29th. Weiss Ratings upgraded Centene from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, October 8th. Robert W. Baird lifted their price objective on Centene from $46.00 to $66.00 and gave the stock a "neutral" rating in a report on Wednesday, July 29th. Finally, Argus upgraded Centene from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a research report on Tuesday, August 11th. Nine analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $70.05.

Insider Activity at Centene

In other news, General Counsel Christopher Koster sold 56,500 shares of the firm's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total transaction of $3,779,850.00. Following the completion of the transaction, the general counsel directly owned 248,854 shares of the company's stock, valued at approximately $16,648,332.60. This trade represents a 18.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.37% of the company's stock.

Centene Company Profile

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company's offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.